LPLesley S. Park

Lesley S. Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lesley S. Park has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Veterans Aging Cohort Study ( VACS )‐National: A Real‐World Data Source Profile

    by Christopher T. Rentsch, Vincent Lo Re, Melissa Skanderson, Kathleen A. McGinnis, Farah Kidwai‐Khan, Charles Alcorn, Anne C. Black, Kristina Crothers, Vincent C. Marconi, Matthew J. Freiberg, et al.

    The Veterans Aging Cohort Study (VACS)‐National is a large, longitudinal real‐world data resource derived from electronic health records within the Department of Veterans Affairs (VA), the largest integrated healthcare system in the United States. As of December 2025, VACS‐National includes > 14.9 million Veterans who have received care in the VA since 2000. It captures information on VA‐related outpatient and inpatient care and includes structured (e.g., diagnostic codes, laboratory results, vital signs, dispensed medical products), semi‐structured (e.g., radiology and pathology reports) and unstructured (e.g., progress notes) fields, collected from over 1300 points of care nationwide. Its longitudinal structure supports extended follow‐up across demographically and clinically diverse populations within an integrated healthcare system. Key features for pharmacoepidemiological research include near real‐time availability of data on dispensed medications, including biologics, vaccines, and devices; routinely‐collected laboratory measurements; and computable phenotypes, including validated natural language phenotypes. The resource includes linkages to Centers for Medicare and Medicaid Services (CMS) data, VA Community Care data, National Death Index, and deeply phenotyped VACS sub‐cohorts with an extensive library of biomarkers and survey data. VACS‐National has supported a wide range of research, including drug utilization, drug safety, comparative effectiveness, and epidemiologic and health outcomes research. Strengths include its national scale, longitudinal follow‐up, and rich clinical record; limitations include a small proportion of women and potential incomplete capture of care outside the system or not recoverable through linked datasets. VACS‐National provides a comprehensive platform for generating real‐world evidence to inform clinical, regulatory, and public health decision‐making.

  • Open Access

    Data from Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma

    by Jessie Torgersen, Tamar H. Taddei, Lesley S. Park, Dean M. Carbonari, Michael J. Kallan, Kisha Mitchell Richards, Xuchen Zhang, Darshana Jhala, Norbert Bräu, Robert Homer, et al.

    Background:The incidence of hepatocellular carcinoma (HCC) is substantially higher among HIV-infected (HIV+) than uninfected persons. It remains unclear if HCC in the setting of HIV infection is morphologically distinct or more aggressive.Methods:We evaluated differences in tumor pathology in a cohort of HIV+ and uninfected patients with microscopically confirmed HCC in the Veterans Aging Cohort Study from 2000 to 2015. We reviewed pathology reports and medical records to determine Barcelona Clinic Liver Cancer stage (BCLC), HCC treatment, and survival by HIV status. Multivariable Cox regression was used to determine the hazard ratio [HR; 95% confidence interval (CI)] of death associated with HIV infection after microscopic confirmation.Results:Among 873 patients with HCC (399 HIV+), 140 HIV+ and 178 uninfected persons underwent liver tissue sampling and had microscopically confirmed HCC. There were no differences in histologic features of the tumor between HIV+ and uninfected patients, including tumor differentiation (well differentiated, 19% vs. 28%, P = 0.16) and lymphovascular invasion (6% vs. 7%, P = 0.17) or presence of advanced hepatic fibrosis (40% vs. 39%, P = 0.90). There were no differences in BCLC stage (P = 0.06) or treatment (P = 0.29) by HIV status. After adjustment for risk factors, risk of death was higher among HIV-infected than uninfected patients (HR = 1.37; 95% CI, 1.02–1.85).Conclusions:We found no differences in HCC tumor characteristics or background hepatic parenchyma by HIV status, yet HIV was associated with poorer survival. Of note, pathology reports often omitted these characteristics.Impact:Systematic evaluation of HCC pathology by HIV status is needed to understand tumor characteristics associated with improved survival.

  • Open Access

    Supplementary Tables 1-9 from Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma

    by Jessie Torgersen, Tamar H. Taddei, Lesley S. Park, Dean M. Carbonari, Michael J. Kallan, Kisha Mitchell Richards, Xuchen Zhang, Darshana Jhala, Norbert Bräu, Robert Homer, et al.

    Supplemental Table 1. Current Procedural Terminology (CPT) codes identifying treatments for hepatocellular carcinoma. Supplemental Table 2. Clinical characteristics of patients with confirmed hepatocellular carcinoma diagnosis in the Veterans Aging Cohort Study (2000-2015), by diagnostic modality. Supplemental Table 3. Factors associated with all-cause mortality following liver tissue sampling among patients with microscopically confirmed hepatocellular carcinoma in the Veterans Aging Cohort Study (2000-2015), after additionally adjusting for year of liver tissue sampling. Supplemental Table 4. Factors associated with all-cause mortality following liver tissue sampling among patients with microscopically confirmed hepatocellular carcinoma in the Veterans Aging Cohort Study (2000-2015), addressing missing tumor differentiation data. In this analysis, missing tumor differentiation data was replaced with a poorly-differentiated result for HIV+ patients, while missing values for uninfected patients were replaced with a well-differentiated result. Supplementary Table 5. Factors associated with all-cause mortality following liver tissue sampling among patients with microscopically confirmed hepatocellular carcinoma in the Veterans Aging Cohort Study (2000-2015), with pathologically-defined advanced hepatic fibrosis. Supplemental Table 6. Factors associated with all-cause mortality following liver tissue sampling among patients with microscopically confirmed hepatocellular carcinoma in the Veterans Aging Cohort Study (2000-2015), with advanced hepatic fibrosis defined by a composite of either a pathologic definition of advanced hepatic fibrosis or FIB-4 >3.25 for those without pathologic data. Supplemental Table 7. Factors associated with all-cause mortality following liver tissue sampling among patients with microscopically confirmed hepatocellular carcinoma in the Veterans Aging Cohort Study (2000-2015), after excluding patients with any hepatocellular carcinoma treatment prior to the date of liver tissue sampling. Supplemental Table 8. Barcelona Clinic Liver Cancer stage of hepatocellular carcinoma, by HIV status and diagnostic modality. Supplemental Table 9. Factors associated with all-cause mortality following hepatocellular carcinoma diagnosis in the Veterans Aging Cohort Study (2000-2015), adjusting for diagnostic modality.

  • COVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration

    by Elena M. Soyer, Kathleen A. McGinnis, Amy C. Justice, Evelyn Hsieh, Maria C. Rodriguez-Barradas, Emily C. Williams, Lesley S. Park

    Research regarding HIV, substance use disorders (SUD), and SARS-CoV-2 infections after COVID-19 vaccination is limited. In the Veterans Aging Cohort Study (VACS)–HIV cohort, we followed vaccinated persons with HIV (PWH) and without HIV (PWoH) from 12/2020 to 3/2022 and linked SARS-CoV-2 test results for laboratory-confirmed breakthrough infection through 9/2022. We examined associations of substance use (alcohol use disorder [AUD], other SUD, smoking status) and HIV status and severity with breakthrough infections, using Cox proportional hazards regression hazard ratios (HR). To test for potential interactions between substance use and HIV, we fit survival models with a multiplicative interaction term. Among 24,253 PWH and 53,661 PWoH, 8.0% of PWH and 7.1% of PWoH experienced COVID-19 breakthrough. AUD (HR 1.42, 95% CI 1.32, 1.52) and other SUD (HR 1.49, 95% CI 1.39, 1.59) were associated with increased risk of breakthrough, and this was similar by HIV status (p-interaction > 0.09). Smoking was not associated with breakthrough. Compared to PWoH, PWH at all HIV severity levels had increased risk of breakthrough ranging from 9% for PWH with CD4 count ≥ 500 cells/µl (HR 1.09, 95% CI 1.02, 1.17) to 59% for PWH with CD4 count < 200 (HR 1.59, 95% CI 1.31, 1.92). Patients with AUD (HR 1.42, 95% CI 1.33, 1.52) and other SUD (HR 1.48, 95% CI 1.38, 1.59) had increased COVID-19 breakthrough risk, regardless of HIV status. HIV was associated with breakthrough; risk was greatest among PWH with lower CD4 count. In addition to inhibiting HIV treatment adherence and increasing HIV progression, AUD and other SUD may increase COVID-19 breakthrough risk.


  • Open Access

    Identification of hepatic steatosis among persons with and without HIV using natural language processing

    by Jessie Torgersen, Melissa Skanderson, Farah Kidwai-Khan, Dean M. Carbonari, Janet P. Tate, Lesley S. Park, Debika Bhattacharya, Joseph K. Lim, Tamar H. Taddei, Amy C. Justice, et al.

    Background: Steatotic liver disease (SLD) is a growing phenomenon, and our understanding of its determinants has been limited by our ability to identify it clinically. Natural language processing (NLP) can potentially identify hepatic steatosis systematically within large clinical repositories of imaging reports. We validated the performance of an NLP algorithm for the identification of SLD in clinical imaging reports and applied this tool to a large population of people with and without HIV. Methods: Patients were included in the analysis if they enrolled in the Veterans Aging Cohort Study between 2001 and 2017, had an imaging report inclusive of the liver, and had ≥2 years of observation before the imaging study. SLD was considered present when reports contained the terms “fatty,” “steatosis,” “steatotic,” or “steatohepatitis.” The performance of the SLD NLP algorithm was compared to a clinical review of 800 reports. We then applied the NLP algorithm to the first eligible imaging study and compared patient characteristics by SLD and HIV status. Results: NLP achieved 100% sensitivity and 88.5% positive predictive value for the identification of SLD. When applied to 26,706 eligible Veterans Aging Cohort Study patient imaging reports, SLD was identified in 72.2% and did not significantly differ by HIV status. SLD was associated with a higher prevalence of metabolic comorbidities, alcohol use disorder, and hepatitis B and C, but not HIV infection. Conclusions: While limited to those undergoing radiologic study, the NLP algorithm accurately identified SLD in people with and without HIV and offers a valuable tool to evaluate the determinants and consequences of hepatic steatosis.


  • Postoperative Outcomes Associated with the Timing of Surgery After SARS-CoV-2 Infection

    by Ira L. MD Leeds, Lesley S. Park, Kathleen Akgun, Amy Weintrob, Amy C. Justice, Joseph T. Jr Md King

    Objective: Examine the association between prior SARS-CoV-2 infection, interval from infection to surgery, and adverse surgical outcomes. Summary Background Data: Earlier series have reported worse outcomes for surgery after COVID-19 illness, and these findings have led to routinely deferring surgery seven weeks after infection. Methods: We created a retrospective cohort of patients from the US Veterans Health Administration facilities nationwide, April 2020 to September 2022, undergoing surgical procedures. Primary outcomes were 90-day all-cause mortality and 30-day complications. Within surgical procedure groupings, SARS-CoV-2 infected and uninfected patients were matched in a 1:4 ratio. We categorized patients by 2-week intervals from SARS-CoV-2 positive test to surgery. Hierarchical multilevel multivariable logistic regression models were used to estimate the association between infection to surgery interval versus no infection and primary end points. Results: We identified 82,815 veterans undergoing eligible operations (33% general, 27% orthopedic, 13% urologic, 9% vascular), of whom 16,563 (20%) had laboratory-confirmed SARS-CoV-2 infection before surgery. The multivariable models demonstrated an association between prior SARS-CoV-2 infection and increased 90-day mortality (odds ratio (OR) 1.42, 95% CI: 1.08, 1.86) and complications (OR 1.32, 95% CI: 1.11, 1.57) only for patients having surgery within 14 days of infection. ASA-stratified multivariable models showed that the associations between increased 90-day mortality (OR 1.40, 95% CI: 1.12, 1.75) and complications (OR 1.73, 95% CI: 1.34, 2.24) for patients having surgery within 14 days of infection were confined to those with ASA 4-5. Conclusions: In a contemporary surgical cohort, patients with prior SARS-CoV-2 infection only had increased postoperative mortality or complications when they had surgery within 14 days after the positive test. These findings support revising timing recommendations between surgery and prior SARS-CoV-2 infection.


  • Comparison of Stage I Non–Small-Cell Lung Cancer Treatments for Patients Living With HIV: A Simulation Study

    by Keith Sigel, Michael J. Silverberg, Kristina Crothers, Lesley Park, Inna Lishchenko, Xuesong Han, Wendy Leyden, Minal Kale, Kimberly Stone, Carlie Sigel, et al.


  • Open Access

    Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout

    by Alexandra N Lea, Wendy A Leyden, Oleg Sofrygin, Ben J Marafino, Jacek Skarbinski, Sonia Napravnik, Deana Agil, Michael Augenbraun, Lorie Benning, Michael A Horberg, et al.

    Background: People with human immunodeficiency virus (HIV) (PWH) may be at increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We examined HIV status and COVID-19 severity, and whether tenofovir, used by PWH for HIV treatment and people without HIV (PWoH) for HIV prevention, was associated with protection. Methods: Within 6 cohorts of PWH and PWoH in the United States, we compared the 90-day risk of any hospitalization, COVID-19 hospitalization, and mechanical ventilation or death by HIV status and by prior exposure to tenofovir, among those with severe acute respiratory syndrome coronavirus 2 infection between 1 March and 30 November 2020. Adjusted risk ratios (aRRs) were estimated by targeted maximum likelihood estimation, with adjustment for demographics, cohort, smoking, body mass index, Charlson comorbidity index, calendar period of first infection, and CD4 cell counts and HIV RNA levels (in PWH only). Results: Among PWH (n = 1785), 15% were hospitalized for COVID-19 and 5% received mechanical ventilation or died, compared with 6% and 2%, respectively, for PWoH (n = 189 351). Outcome prevalence was lower for PWH and PWoH with prior tenofovir use. In adjusted analyses, PWH were at increased risk compared with PWoH for any hospitalization (aRR, 1.31 [95% confidence interval, 1.20–1.44]), COVID-19 hospitalizations (1.29 [1.15–1.45]), and mechanical ventilation or death (1.51 [1.19–1.92]). Prior tenofovir use was associated with reduced hospitalizations among PWH (aRR, 0.85 [95% confidence interval, .73–.99]) and PWoH (0.71 [.62–.81]). Conclusions: Before COVID-19 vaccine availability, PWH were at greater risk for severe outcomes than PWoH. Tenofovir was associated with a significant reduction in clinical events for both PWH and PWoH.


  • Open Access

    Differences in COVID-19 testing and adverse outcomes by race, ethnicity, sex, and health system setting in a large diverse US cohort

    by Celeena Jefferson, Eric Watson, Julia M. Certa, Kirsha S. Gordon, Lesley S. Park, Gypsyamber D’sOuza, Lorie Benning, Alison G. Abraham, Deana Agil, Sonia Napravnik, et al.

    Background: Racial/ethnic disparities during the first six months of the COVID-19 pandemic led to differences in COVID-19 testing and adverse outcomes. We examine differences in testing and adverse outcomes by race/ethnicity and sex across a geographically diverse and system-based COVID-19 cohort collaboration. Methods: Observational study among adults (≥18 years) within six US cohorts from March 1, 2020 to August 31, 2020 using data from electronic health record and patient reporting. Race/ethnicity and sex as risk factors were primary exposures, with health system type (integrated health system, academic health system, or interval cohort) as secondary. Proportions measured SARS-CoV-2 testing and positivity; attributed hospitalization and death related to COVID-19. Relative risk ratios (RR) with 95% confidence intervals quantified associations between exposures and main outcomes. Results: 5,958,908 patients were included. Hispanic patients had the highest proportions of SARS-CoV-2 testing (16%) and positivity (18%), while Asian/Pacific Islander patients had the lowest portions tested (11%) and White patients had the lowest positivity rates (5%). Men had a lower likelihood of testing (RR = 0.90 [0.89–0.90]) and a higher positivity risk (RR = 1.16 [1.14–1.18]) compared to women. Black patients were more likely to have COVID-19-related hospitalizations (RR = 1.36 [1.28–1.44]) and death (RR = 1.17 [1.03–1.32]) compared with White patients. Men were more likely to be hospitalized (RR = 1.30 [1.16–1.22]) or die (RR = 1.70 [1.53–1.89]) compared to women. These racial/ethnic and sex differences were reflected in both health system types. Conclusions: This study supports evidence of disparities by race/ethnicity and sex during the COVID-19 pandemic that persisted even in healthcare settings with reduced barriers to accessing care. Further research is needed to understand and prevent the drivers that resulted in higher burdens of morbidity among certain Black patients and men.


  • SARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts

    by Lesley S. Park, Kathleen A. McGinnis, Kirsha S. Gordon, Amy C. Justice, Wendy Leyden, Michael J. Silverberg, Jacek Skarbinski, Celeena Jefferson, Michael Horberg, Julia Certa, et al.

    Background: It is not definitively known if persons with HIV (PWH) are more likely to be SARS-CoV-2 tested or test positive than persons without HIV (PWoH). We describe SARS-CoV-2 testing and positivity in 6 large geographically and demographically diverse cohorts of PWH and PWoH in the United States. Setting: The Corona Infectious Virus Epidemiology Team comprises 5 clinical cohorts within a health system (Kaiser Permanente Northern California, Oakland, CA; Kaiser Permanente Mid-Atlantic States, Rockville, MD; University of North Carolina Health, Chapel Hill, NC; Vanderbilt University Medical Center, Nashville, TN; and Veterans Aging Cohort Study) and 1 interval cohort (Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort Study). Methods: We calculated the proportion of patients SARS-CoV-2 tested and the test positivity proportion by HIV status from March 1 to December 31, 2020. Results: The cohorts ranged in size from 1675 to 31,304 PWH and 1430 to 3,742,604 PWoH. The proportion of PWH who were tested for SARS-CoV-2 (19.6%–40.5% across sites) was significantly higher than PWoH (14.8%–29.4%) in the clinical cohorts. However, among those tested, the proportion of patients with positive SARS-CoV-2 tests was comparable by HIV status; the difference in proportion of SARS-CoV-2 positivity ranged from 4.7% lower to 1.4% higher. Conclusions: Although PWH had higher testing proportions compared with PWoH, we did not find evidence of increased positivity in 6 large, diverse populations across the United States. Ongoing monitoring of testing, positivity, and COVID-19–related outcomes in PWH are needed, given availability, response, and durability of COVID-19 vaccines; emergence of SARS-CoV-2 variants; and latest therapeutic options.